In the preceding three months, 12 analysts have released ratings for 10x Genomics TXG, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 5 | 0 | 2 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 1 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 3 | 0 | 3 | 0 | 1 |
Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $33.0, a high estimate of $55.00, and a low estimate of $16.00. Observing a downward trend, the current average is 33.02% lower than the prior average price target of $49.27.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive 10x Genomics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Daniel Arias | Stifel | Lowers | Buy | $25.00 | $53.00 |
| Justin Bowers | Deutsche Bank | Lowers | Hold | $25.00 | $55.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Sell | $16.00 | $26.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $24.00 | $36.00 |
| Tycho Peterson | Jefferies | Announces | Hold | $24.00 | - |
| Dan Leonard | UBS | Lowers | Neutral | $30.00 | $52.00 |
| Derik De Bruin | B of A Securities | Lowers | Neutral | $36.00 | $45.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Sell | $26.00 | $30.00 |
| Dan Brennan | TD Cowen | Lowers | Hold | $32.00 | $57.00 |
| Daniel Arias | Stifel | Lowers | Buy | $53.00 | $63.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $50.00 | $65.00 |
| Justin Bowers | Deutsche Bank | Lowers | Buy | $55.00 | $60.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to 10x Genomics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of 10x Genomics's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of 10x Genomics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on 10x Genomics analyst ratings.
All You Need to Know About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
10x Genomics's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: 10x Genomics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.0%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: 10x Genomics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -42.52%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): 10x Genomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -8.21%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): 10x Genomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.35%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
